Spain Radiopharmaceuticals Market By Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic), By End User (Hospitals and clinics, Medical Imaging centers, Others): Opportunity Analysis and Industry Forecast, 2023-2032
The rise in cancer, cardiovascular, and neurological illness prevalence, the rise in demand for medical imaging, and the rise in product approval for radiopharmaceuticals are the main factors driving the growth of the Spain radiopharmaceuticals market share. The market is growing as a result of an increase in radiopharmaceutical R&D.
The alarming increase in the prevalence of chronic illnesses, including cancer, cardiovascular diseases, and neurological diseases is a crucial factor propelling the market for radiopharmaceuticals. The demand for radiopharmaceuticals is increased by such disease's rising prevalence as well as the corresponding rise in diagnosis and treatment needs. To identify and treat cancer, radiopharmaceuticals are injected into the body, where they gather in malignant tissues, enabling the detection and management of the illnesses.
Additionally, the market for radiopharmaceuticals is being driven by an increase in PET imaging and a rise in demand for accurate diagnostics. Moreover, during the forecast period, rising physician knowledge of nuclear medicine is anticipated to fuel market expansion for radiopharmaceuticals. The International Atomic Energy Agency had estimated that by 2020, 80% of medical imaging will be used annually to diagnose diseases, including cancer.
Moreover, in March 2023, AtomVie Global Radiopharma Inc., a company in the radiopharmaceutical sector, constructed an industry-leading Contract Development and Manufacturing Organisation (CDMO) facility for radiopharmaceuticals in Ontario, Canada. The brand-new facility will be used exclusively to distribute radiopharmaceuticals medicines around the world. A new subsidiary, Blue Earth Therapeutics, was also launched by Bracco Imaging in March 2022 with the goal of creating the next generation of therapeutic radiopharmaceutical technology. The existence of the radiopharmaceuticals sector offers a chance for the market for radiopharmaceuticals to expand.
On the other hand, side effects of radiopharmaceuticals such as drowsiness, fainting, fever, flushing, headache, nausea, vomiting, stomach pain, skin rashes, and difficulty in breathing are anticipated to limit the growth of the market during the forecast period.
The COVID-19 pandemic has had a significant impact on radiopharmaceuticals market. The pandemic has caused major disruptions to the production and supply of radiopharmaceuticals to the nuclear medicine department, resulting in shortages of radiopharmaceuticals. According to the European Journal of Nuclear Medicine and Molecular Imaging, in July 2021, around 81% of the countries reported a decrease in diagnostic scintigraphy procedures during the COVID-19 pandemic.
INSYSBIO, INDUVAC, B-NUCLEAR, GE HEALTHCARE, NUCLEUS BIOTEK, NUCLEON, TRADEO, EGAMMA, PHARMALINE, MEDIPHARMA are some of the companies operating in the market.
Key Benefits For Stakeholders
Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
Analyze the key strategies adopted by major market players in Spain radiopharmaceuticals market.
Assess and rank the top factors that are expected to affect the growth of Spain radiopharmaceuticals market.
Top player positioning provides a clear understanding of the present position of market players.
Detailed analysis of the Spain radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.
Identify key investment pockets for various offerings in the market.
New Product Development/ Product Matrix of Key Players
Patient/epidemiology data at country, region, global level
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)
SWOT Analysis
Key Market Segments
By Type
Diagnostic
Therapeutic
By End User
Hospitals and clinics
Medical Imaging centers
Others
By Radioisotope
Fluorine 18
Iodine I
Gallium 68
Others
Technetium 99m
By Application
Cancer
Cardiology
Others
Key Market Players
INSYSBIO
INDUVAC
B-NUCLEAR
GE HEALTHCARE
NUCLEUS BIOTEK
NUCLEON
TRADEO
EGAMMA
PHARMALINE
MEDIPHARMA
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits to the Stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Impacting Factors
- 3.2.2. Top Investment Pockets
- 3.3. Porter’s Five Forces Analysis
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
- 3.5. COVID-19 Impact Analysis on the market
- CHAPTER 4: SPAIN RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
- 4.1. Overview
- 4.1.1. Market Size and Forecast, By Radioisotope
- 4.2. Technetium 99m
- 4.3. Fluorine 18
- 4.4. Iodine I
- 4.5. Gallium 68
- 4.6. Others
- CHAPTER 5: SPAIN RADIOPHARMACEUTICALS MARKET, BY APPLICATION
- 5.1. Overview
- 5.1.1. Market Size and Forecast, By Application
- 5.2. Cancer
- 5.3. Cardiology
- 5.4. Others
- CHAPTER 6: SPAIN RADIOPHARMACEUTICALS MARKET, BY TYPE
- 6.1. Overview
- 6.1.1. Market Size and Forecast, By Type
- 6.2. Diagnostic
- 6.3. Therapeutic
- CHAPTER 7: SPAIN RADIOPHARMACEUTICALS MARKET, BY END USER
- 7.1. Overview
- 7.1.1. Market Size and Forecast, By End User
- 7.2. Hospitals and clinics
- 7.3. Medical Imaging centers
- 7.4. Others
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top player positioning, 2022
- CHAPTER 9: COMPANY PROFILES
- 9.1. Company 1
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
- 9.2. Company 2
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
- 9.3. Company 3
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
- 9.4. Company 4
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
- 9.5. Company 5
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
- 9.6. Company 6
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
- 9.7. Company 7
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
- 9.8. Company 8
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
- 9.9. Company 9
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
- 9.10. Company 10
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments
- LIST OF TABLES
- TABLE 01. SPAIN RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
- TABLE 02. SPAIN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 03. SPAIN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 04. SPAIN RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 05. COMPANY 1: KEY EXECUTIVES
- TABLE 06. COMPANY 1: COMPANY SNAPSHOT
- TABLE 07. COMPANY 1: OPERATING SEGMENTS
- TABLE 08. COMPANY 1: PRODUCT PORTFOLIO
- TABLE 09. COMPANY 1: KEY STRATERGIES
- TABLE 10. COMPANY 2: KEY EXECUTIVES
- TABLE 11. COMPANY 2: COMPANY SNAPSHOT
- TABLE 12. COMPANY 2: OPERATING SEGMENTS
- TABLE 13. COMPANY 2: PRODUCT PORTFOLIO
- TABLE 14. COMPANY 2: KEY STRATERGIES
- TABLE 15. COMPANY 3: KEY EXECUTIVES
- TABLE 16. COMPANY 3: COMPANY SNAPSHOT
- TABLE 17. COMPANY 3: OPERATING SEGMENTS
- TABLE 18. COMPANY 3: PRODUCT PORTFOLIO
- TABLE 19. COMPANY 3: KEY STRATERGIES
- TABLE 20. COMPANY 4: KEY EXECUTIVES
- TABLE 21. COMPANY 4: COMPANY SNAPSHOT
- TABLE 22. COMPANY 4: OPERATING SEGMENTS
- TABLE 23. COMPANY 4: PRODUCT PORTFOLIO
- TABLE 24. COMPANY 4: KEY STRATERGIES
- TABLE 25. COMPANY 5: KEY EXECUTIVES
- TABLE 26. COMPANY 5: COMPANY SNAPSHOT
- TABLE 27. COMPANY 5: OPERATING SEGMENTS
- TABLE 28. COMPANY 5: PRODUCT PORTFOLIO
- TABLE 29. COMPANY 5: KEY STRATERGIES
- TABLE 30. COMPANY 6: KEY EXECUTIVES
- TABLE 31. COMPANY 6: COMPANY SNAPSHOT
- TABLE 32. COMPANY 6: OPERATING SEGMENTS
- TABLE 33. COMPANY 6: PRODUCT PORTFOLIO
- TABLE 34. COMPANY 6: KEY STRATERGIES
- TABLE 35. COMPANY 7: KEY EXECUTIVES
- TABLE 36. COMPANY 7: COMPANY SNAPSHOT
- TABLE 37. COMPANY 7: OPERATING SEGMENTS
- TABLE 38. COMPANY 7: PRODUCT PORTFOLIO
- TABLE 39. COMPANY 7: KEY STRATERGIES
- TABLE 40. COMPANY 8: KEY EXECUTIVES
- TABLE 41. COMPANY 8: COMPANY SNAPSHOT
- TABLE 42. COMPANY 8: OPERATING SEGMENTS
- TABLE 43. COMPANY 8: PRODUCT PORTFOLIO
- TABLE 44. COMPANY 8: KEY STRATERGIES
- TABLE 45. COMPANY 9: KEY EXECUTIVES
- TABLE 46. COMPANY 9: COMPANY SNAPSHOT
- TABLE 47. COMPANY 9: OPERATING SEGMENTS
- TABLE 48. COMPANY 9: PRODUCT PORTFOLIO
- TABLE 49. COMPANY 9: KEY STRATERGIES
- TABLE 50. COMPANY 10: KEY EXECUTIVES
- TABLE 51. COMPANY 10: COMPANY SNAPSHOT
- TABLE 52. COMPANY 10: OPERATING SEGMENTS
- TABLE 53. COMPANY 10: PRODUCT PORTFOLIO
- TABLE 54. COMPANY 10: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 01. SPAIN RADIOPHARMACEUTICALS MARKET, 2022-2032
- FIGURE 02. SEGMENTATION OF SPAIN RADIOPHARMACEUTICALS MARKET, 2022-2032
- FIGURE 03. TOP INVESTMENT POCKETS IN SPAIN RADIOPHARMACEUTICALS MARKET (2023-2032)
- FIGURE 04. PORTER FIVE-1
- FIGURE 05. PORTER FIVE-2
- FIGURE 06. PORTER FIVE-3
- FIGURE 07. PORTER FIVE-4
- FIGURE 08. PORTER FIVE-5
- FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: SPAIN RADIOPHARMACEUTICALS MARKET
- FIGURE 10. SPAIN RADIOPHARMACEUTICALS MARKET,BY RADIOISOTOPE, 2022 ($MILLION)
- FIGURE 11. SPAIN RADIOPHARMACEUTICALS MARKET,BY APPLICATION, 2022 ($MILLION)
- FIGURE 12. SPAIN RADIOPHARMACEUTICALS MARKET,BY TYPE, 2022 ($MILLION)
- FIGURE 13. SPAIN RADIOPHARMACEUTICALS MARKET,BY END USER, 2022 ($MILLION)
- FIGURE 14. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 15. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 16. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 17. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 18. COMPETITIVE DASHBOARD
- FIGURE 19. COMPETITIVE HEATMAP: SPAIN RADIOPHARMACEUTICALS MARKET
- FIGURE 20. TOP PLAYER POSITIONING, 2022
- FIGURE 21. COMPANY 1: NET SALES, 2020-2022* ($MILLION)
- FIGURE 22. COMPANY 1: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 23. COMPANY 1: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 24. COMPANY 2: NET SALES, 2020-2022* ($MILLION)
- FIGURE 25. COMPANY 2: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 26. COMPANY 2: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 27. COMPANY 3: NET SALES, 2020-2022* ($MILLION)
- FIGURE 28. COMPANY 3: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 29. COMPANY 3: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 30. COMPANY 4: NET SALES, 2020-2022* ($MILLION)
- FIGURE 31. COMPANY 4: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 32. COMPANY 4: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 33. COMPANY 5: NET SALES, 2020-2022* ($MILLION)
- FIGURE 34. COMPANY 5: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 35. COMPANY 5: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 36. COMPANY 6: NET SALES, 2020-2022* ($MILLION)
- FIGURE 37. COMPANY 6: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 38. COMPANY 6: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 39. COMPANY 7: NET SALES, 2020-2022* ($MILLION)
- FIGURE 40. COMPANY 7: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 41. COMPANY 7: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 42. COMPANY 8: NET SALES, 2020-2022* ($MILLION)
- FIGURE 43. COMPANY 8: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 44. COMPANY 8: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 45. COMPANY 9: NET SALES, 2020-2022* ($MILLION)
- FIGURE 46. COMPANY 9: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 47. COMPANY 9: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 48. COMPANY 10: NET SALES, 2020-2022* ($MILLION)
- FIGURE 49. COMPANY 10: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 50. COMPANY 10: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook